1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Latest R&D Spending Benchmark Study Puts Cancer Drug Costs At $648M

 
• By Cathy Kelly

Estimate in JAMA paper is significantly lower than often-cited $2.6bn in research and development costs projected in a 2014 study by Tufts Center for the Study of Drug Development.

female scientist working with microscope

The cost to successfully research and develop a cancer drug is $648m, according to an analysis by Vinay Prasad, Oregon Health and Science University, and Sham Mailankody, Memorial Sloan Kettering Cancer Center, published in the Journal of the American Medical Association Sept. 11.

The study represents the latest attempt to calculate the cost of biopharma R&D and how it relates to drug prices and revenues.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

Could EU Collective Procurement Counter US Most Favored Nation Policy?

 
• By Francesca Bruce

Joint procurement, if used by member states to respond to potential pricing and access challenges caused by a US most favored nations pricing policy, would cause more uncertainty for pharmaceutical companies, warn industry representatives.

US FDA’s Familiar Drug Pricing To-Do List

 
• By Michael McCaughan

President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.

US Most Favored Nations Policy: Higher Drug Spending In Germany Is ‘Difficult To Imagine’

 
• By Francesca Bruce

Germany’s federal health care decision-making body, the G-BA, tells the Pink Sheet that German drug prices are fair and speculation of price rises in the market due to the US MFN policy is fear mongering.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

More from Market Access